npm-crop

Nicholas P. Marsico, M.D., F.A.C.S.

Nicholas Marsico, M.D., F.A.C.S. is a board certified ophthalmologist who specializes in refractive surgery and the treatment of corneal diseases.

Nicholas P. Marsico, M.D., F.A.C.S. is a board certified ophthalmologist who performs all aspects of surgery on the anterior segment of the eye including cataract extraction, glaucoma surgery and various forms of corneal transplantation including penetrating keratoplasty and DSAEK.  He is fellowship trained in LASIK laser vision correction as well as other forms of refractive surgery and in the treatment of corneal diseases.  In addition, Dr. Marsico manages general ophthalmology patients such as those with diabetic eye disease and macular degeneration utilizing advanced lasers and the latest treatment techniques to optimize patient outcomes.

Dr. Marsico received his undergraduate education at the Ohio State University in Columbus, Ohio where he graduated Summa Cum Laude with Honors and was inducted into the Phi Beta Kappa national academic honor society.  Thereafter, he received his M.D. degree from the Ohio State University College of Medicine.  He went on to complete his ophthalmology residency at Boston University and subspecialty fellowship training in Cornea / External Diseases and Refractive Surgery at the University of Pittsburgh Eye and Ear Institute.  After practicing in such places as Ohio and North Carolina, Dr. Marsico joined the East West Eye Institute in July of 2004.  He is a member of the American Academy of Ophthalmology, the American Society of Cataract and Refractive Surgery, the International Society of Refractive Surgery, the California Academy of Ophthalmology, and the Los Angeles Society of Ophthalmology.

 

EDUCATION

FELLOWSHIP: Corneal/External Disease & Refractive Surgery
The Eye & Ear Institute, University of Pittsburgh, Pittsburgh, PA 2000-2001

RESIDENCY: Boston University, Boston, MA 1997-2000
Chief resident, 2000

INTERSHIP: Mount Carmel Medical Center, Transitional Year internship
Columbus, OH 1996-1997

MEDICAL SCHOOL: Ohio State University College of Medicine, Columbus, OH 1992-1996
Doctor of Medicine degree 1996

UNDERGRADUATE: Ohio State University, Columbus, OH 1988-1992
Bachelor of Science Degree, Biology Major, History Minor, 1992

 

PROFESSIONAL POSITIONS:

East West Eye Institute, Inc. Los Angeles, CA  July 2004 – present

Eye Specialists, Inc. Circleville, OH  March 2002 – June 2004

Carolina Eye Associates, PA Raleigh, NC  July 2001 – Jan 2002

 

HONORS AND AWARDS

Phi Beta Kappa

Summa Cum Laude

Liberal Arts Honors

Ohio State University College of Medicine Landacre Day research award recipient

Roessler Memorial Research Scholarship, Ohio State University College of Medicine 1993 and 1994

 

PROFESSIONAL AND ACADEMIC SOCIETIES

Diplomate American Board of Ophthalmology – Board Certified October 2001, Recertified October 2011

Fellow of the American College of Surgeons

American Academy of Ophthalmology

American Society of Cataract and Refractive Surgery

International Society of Refractive Surgery

California Academy of Eye Physicians and Surgeons

Los Angeles Society of Ophthalmology

 

HOSPITAL AFFILIATIONS

St. Vincent Medical Center – 04/19/05 to present

–  2131 W. Third St., Los Angeles, CA  90057-0992

Good Samaritan Hospital – 09/23/04 to present

–   1225 Wilshire Blvd. Los Angeles, CA  90017

Community Hospital of Gardena – 09/13/04 to present

– 1246 West 155th St. Gardena, CA  90247

Clinton Memorial Hospital – 8/03 to 7/04

–  610 West Main St. Wilmington, OH  45177

Berger Hospital – 9/25/02 to 6/04

-600 N. Pickaway St., Circleville, OH  43113

Rex Hospital – 9/11/01 to 2/26/02

– 4420 Lake Boone Trail, Raleigh, NC  27607

Raleigh Community Hospital – 9/13/01 to 2/26/02

– 3400 Wake Forest Rd, Raleigh, NC  27609

 

CLINICAL TRIALS

October 2012 – Principal Investigator: GMA-LAS-12-023: A Multi-Center, Double-Masked, Randomized, Active-And-Placebo-Controlled Evaluation of the Efficacy of Action of Lastacaft (Alcaftadine 0.25%) Ophthalmic Solution Compared to Pataday and Placebo in the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis

June 2012 – Prinicipal Investigator: OMS302-ILR-004: A Phase 3 Randomized, Double-Masked, Placebo-Controlled Study of the Pharmocokinetics of OMS302 and the Effect of OMS302 on Intraoperative Pupil Diameter and Early Postoperative Pain in Subjects Undergoing Intraocular Lens Replacement with Phacoemulsification

October 2011 – Principal Investigator:  OMS302-ILR-003:  A Phase 3 Randomized, Double-Masked, Placebo-Controlled Study of the Effect of OMS302 on Intraoperative Pupil Diameter and Early Postoperative Pain in Subjects Undergoing Intraocular Lens Replacement With Phacoemulsification

July 2011 – Principal Investigator: B & L 661: A Study to Evaluate the Safety and Efficacy of a New Silicone Hydrogel Contact Lens Design

June 2011 – Principal Investigator: B & L 637: A Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Multicenter, Exploratory Study Assessing the Safety and Efficacy of BOL-303242-X Ophthalmic Suspension in Dry Eye Syndrome

April 2011 – Principal Investigator: A Study to Evaluate the Safety and Efficacy of a Novel Contact Lens Used in Healthy, Normal Volunteers that Live in an Urban Environment.

November 2010 – Principal Investigator: B & L Study 685 / 10-100-0021: A Multi-Center, Randomized, Evaluation of the Efficacy of BOL-303242-X (Maprocorat) Ophthalmic Suspension, (0.3%, 2%, and 3%) Compared to Vehicle in a Modified Conjunctival Allergen Challenge (CAC)

November 2010 – Principal Investigator:  OMS302 C09-001:  “A Study of Phenylephrine HCl’s and Ketorolac Tromethamine’s Ability, Alone and in Combination, to Maintain Mydriasis and Relieve Pain and Inflammation in Subjects Undergoing Unilateral Cataract Extraction with Lens Replacement (CELR)”

September 2010 – Principal Investigator: FOV1101/CLIN/202//P: A Multi-Center, Randomized, Double-Masked Evaluation of the Efficacy of Co-Administration of FOV1101-00 (Cyclosporine 0.01% or 0.02%) and Prednisolone Acetate 0.12% (Pred Mild) Compared to its Components and Vehicle in Patients with Mild Ongoing Ocular Allergic Inflammation

May 2010 – Principal Investigator: Aciex Therapeutics 10-100-0005: A Multi-Center, Randomized, Double-Masked Evaluation of the Efficacy of Cetirizine 0.1% / Fluticasone 0.005% Ophthalmic Solution Compared to its Components and Vehicle in a Modified Conjunctival Allergen Challenge (CAC) Model During Pollen Season

April 2010 – Principal Investigator: B & L 572 / 07-003-21: A Multi-Center, Double-Masked, Randomized, Vehicle and Active Controlled Evaluation of the Onset and Duration of Action of Ketonaph (Ketotifen Fumarate 0.025%, Naphazoline HC1 0.05%) Ophthalmic Solution in the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis

March 2009 – Principal Investigator: A Multi-Center, Randomized, Double-Masked Evaluation of the Efficacy of Co-Administration of FOV1101-00 (Cyclosporine 0.01% or 0.02%) and Prednisolone Acetate 0.12% (Pred Mild®) Compared to its Components and Vehicle in Patients with Mild Ongoing Ocular Allergic Inflammation.

June 2008 – Principal Investigator:  A Study to Evaluate the Clinical Performance of a Novel Multi-Purpose Solution.

January 2008 – Sub Investigator:  Multi Center, Double Masked, Placebo Controlled, Evaluation of the Onset and Duration of Action of Two Concentrations of Bepotastine Besilate Ophthalmic Solution in the Conjunctival Allergen Challenge

November 2007 – Sub Investigator:  Multi – Center, randomized, Double Masked, Placebo-Controlled, Parallel-Group Study Evaluating the Safety of a Novel Contact Lens Used Daily in Healthy, Normal Volunteers.

August 2007 – Sub Investigator: The efficacy, safety and tolerability of travoprost bak free 0.0004% (Travatan Z) compared to prior treatment with Latanoprost 0.0005%) in patients of Japanese origin.

May 2006 – Sub Investigator:  Multi-Centered Evaluation of the Efficacy and Clinical Performance of the Duration of Action of Patanol Ophthalmic Solution vs. Livostin Ophthalmic Suspension Using the Conjunctival Allergen Challenge Model of Acute Allergic Conjunctivitis in Japanese Subjects.

February 2006 – Principal Investigator:  A study to evaluate the clnical and microbial eficacy of 0.6% ISV-403 compared to Vigamox in the treatment of bacterial conjunctivitis.

 

POSTER PRESENTATIONS

Alloderm Grafting in the Irradiated Socket. Poster. European Society of Oculoplastic and Reconstructive Surgery,
Istanbul Turkey, Sept. 1999

Vascular Changes in Diabetic Retina – Modified trypsin-digestion technique. Poster. ARVO, Sarasota Florida, 1994

Geographical Distribution of Diabetic Retinal Vascular Abnormalities. Poster. ARVO, Sarasota Florida, 1994

 

TEACHING AFFILIATION

Mount Carmel Medical Center, clinical ophthalmology instructor for internal medicine residents, June 2002 – June 2004

 

INTERESTS

Fitness, watersports, travel